published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] NIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] 0.77[0.54; 1.09]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,295moderatenot evaluable deaths (time to event analysis only)detailed resultsNIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04] 0.70[0.47; 1.04]NIH NIAID ACTT-1, 202010%1,059moderatenot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] NIH NIAID ACTT-1, 2020 1.32 [1.12; 1.55] 1.30[1.12; 1.51]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] 1.21[0.64; 2.28]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] 1.37[0.79; 2.39]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] 0.99[0.18; 5.51]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] 1.23[0.87; 1.74]CAP-China (Wang et al.), 202010%237lownot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233lownot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] 0.71[0.55; 0.92]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-19 05:59 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 510 - roots T: 290